New vaccine could stop deadly lassa fever
NCT ID NCT06546709
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing a new vaccine called LASSARAB, designed to protect against Lassa fever, a serious viral illness. The vaccine uses a modified rabies virus to deliver the Lassa antigen and includes an adjuvant to boost the immune response. 55 healthy adults will receive two doses to see if it is safe and triggers an immune response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- LASSARAB vaccine (rabies-vectored Lassa fever vaccine with aPHAD-SE adjuvant)
- What this could lead to
- If successful, this could pave the way for a vaccine to prevent Lassa fever, a serious viral disease common in West Africa.
- What could go wrong
- This is a very early (Phase 1) trial with only 55 people, so it's primarily checking safety. The vaccine may not trigger a strong enough immune response or could cause side effects. Success in animals doesn't guarantee it will work in humans.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LASSA FEVER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Maryland, Baltimore, University of Maryland School of Medicine, Center for Vaccine Development and Global Health
Baltimore, Maryland, 21201, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.